[Isoprinosine treatment of herpes zoster. Résults of a control study in 36 subjects (author's transl)].
A double-blind trial comparing isoprinosine with a placebo was conducted in 36 subjects. Improvement of skin lesions was significantly better in the treatment group (p less than or equal to 0.01). Before entering the trial, patients in the treatment group had significantly more severe pain than those in the placebo group (p less than or equal to 0.01), the difference disappeared after treatment. Healing of skin lesions was more rapid in patients treated before the 5th day of the disease (p less than or equal to 0.03). None of the subjects developed post-zoster neuralgia. The clinical effects of the drugs were accompanied by a decrease in serum rosette activity. We consider isoprinosine as an innocuous and effective treatment of herpes zoster.
D000328:Adult; D000368:Aged; D004311:Double-Blind Method; D004341:Drug Evaluation; D005260:Female; D006562:Herpes Zoster / Q000188:drug therapy*; D006801:Humans; D007288:Inosine / Q000031:analogs & derivatives*; D007542:Inosine Pranobex / Q000008:administration & dosage / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged
D007288:Inosine; D007542:Inosine Pranobex
Traitement du zona par l'isoprinosine. Résultats d'une étude controlée chez 36 malades.